Biotech company Biogen (NASDAQ: BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for.

Biogen beat analysts’ revenue expectations last quarter, reporting revenues of $2.48 billion, up 1.9% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates.

Is Biogen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Biogen’s revenue to decline 7.8% year on year, a reversal from the 7.3% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Biogen has a history of exceeding Wall Street’s expectations.

With Biogen being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for biotechnology stocks. However, investors in the segment have had steady hands going into earnings, with share prices up 1.9% on average over the last month. Biogen is down 7.2% during the same time .

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.